Recursion Pharmaceuticals, Inc. (RXRX) Operating cash flow 2019–2025
Recursion Pharmaceuticals, Inc. (RXRX) annual operating cash flow history from SEC filings — net cash provided by operating activities each fiscal year.
-$371.8MFY2025 · since FY2019: -$57.0M → -$371.8M
| Fiscal year | Value | YoY |
|---|---|---|
| FY2025 | -$371.8M | -3.5% |
| FY2024 | -$359.2M | -24.8% |
| FY2023 | -$287.8M | -244.5% |
| FY2022 | -$83.5M | +47.3% |
| FY2021 | -$158.6M | -249.4% |
| FY2020 | -$45.4M | +20.4% |
| FY2019 | -$57.0M | — |
Source: SEC XBRL filings · For reference only · Not investment advice
More RXRX financial trends
RXRX RevenueRXRX Net incomeRXRX Net marginRXRX Gross profitRXRX Gross marginRXRX Operating incomeRXRX Operating marginRXRX Free cash flowRXRX Capital expendituresRXRX Return on equityRXRX Stock buybacksRXRX Dividends paidRXRX Total assetsRXRX Total liabilitiesRXRX Shareholders’ equityRXRX overview →